Biogen Board Appoints Two New Independent Directors

Core Insights - Biogen Inc. has appointed two new independent directors, Lloyd B. Minor, M.D., and Sir Menelas Pangalos, Ph.D., to enhance its Board of Directors, effective October 1, 2024, and January 1, 2025, respectively [1][2] Group 1: New Appointments - Dr. Lloyd B. Minor is the Dean of the Stanford University School of Medicine and has extensive experience in leading health and medicine strategy, previously serving as Provost at Johns Hopkins University [2][3] - Sir Menelas Pangalos was the Executive Vice President of Biopharmaceuticals R&D at AstraZeneca, where he oversaw R&D from discovery to late-stage development, and has held senior roles at Pfizer, Wyeth, and GSK [4][5] Group 2: Contributions to Biogen - The new directors are expected to bring significant experience in R&D within the life sciences and biopharmaceutical industries, contributing to Biogen's portfolio and long-term growth [2][6] - Biogen's President and CEO, Christopher A. Viehbacher, emphasized that their collective expertise will be instrumental in advancing the company into its next chapter of sustainable growth [6] Group 3: Company Background - Biogen, founded in 1978, is a leading biotechnology company focused on innovative science to deliver new medicines and create value for shareholders and communities [7]